E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 1/23/2020 in the Prospect News Convertibles Daily.

New Issue: Elanco Animal Health prices $550 million three-year equity units to yield 5%, up 20%

By Abigail W. Adams

Portland, Me., Jan. 23 – Elanco Animal Health Inc. priced $550 million, or 11 million units, of three-year par of $50 tangible equity units after the market close on Wednesday at par to yield 5% with a threshold appreciation premium of 20%, according to an FWP filing with the Securities and Exchange Commission.

Pricing came in line with talk for a fixed dividend of 5% and a fixed threshold appreciation premium of 20%, according to a market source.

Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., J.P. Morgan Securities LLC and BofA Securities Inc. were joint bookrunners for the registered offering.

The equity units are composed of a prepaid stock purchase contract and a senior amortizing note with a principal amount of $7.2007 per note that bears interest at an annual rate of 2.75%.

The stock purchase contracts are callable on or after Nov. 1, 2020 at the maximum settlement rate. They are putable upon a fundamental change.

The equity units priced concurrently with an upsized common stock offering of 22,694,732 shares, which priced at $32.00 a share.

The common stock offering carries an upsized greenshoe of 2,269,473 shares. The initial size of the secondary offering was 19,159,866 shares with a greenshoe of 1,915,987.

Net proceeds from the common stock offering are expected to be $697.9 million, or $767.9 million if the greenshoe is exercised in full.

Net proceeds from the equity units are expected to be $528.1 million. Proceeds will be used to fund a portion of the previously announced acquisition of Bayer AG’s animal health business.

If the acquisition is not completed, proceeds will be used for general corporate purposes.

Elanco Animal Health is a Greenfield, Ind.-based global animal health company.

Issuer:Elanco Animal Health Inc.
Securities:Tangible equity units
Amount:$550 million, or 11 million units
Maturity:Feb. 1, 2023
Bookrunners:Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., J.P. Morgan Securities LLC and BofA Securities Inc.
Co-managers:Barclays, BNP Paribas Securities Corp., Mizuho Securities USA Inc., MUFG and Stifel, Nicolaus & Co. Inc.
Dividend:5%
Price:$50-par
Yield:5%
Premium:20%
Conversion price:$38.40
Conversion rate:Minimum 1.3021, maximum 1.5625
Call options:On or after Nov. 1, 2020 at the maximum settlement rate
Put:Upon a fundamental change
Pricing date:Jan. 22
Settlement date:Jan. 27
Distribution:Registered
Talk:Fixed dividend of 5% and a fixed threshold appreciation premium of 20%
Stock symbol:NYSE: ELAN
Stock reference price:$32.00 in concurrent offering
Market capitalization:$12.02 billion

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.